Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Rating of “Buy” by Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $20.57.

A number of research firms have weighed in on CLBT. Needham & Company LLC raised their price target on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. TD Cowen upped their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Finally, Craig Hallum upped their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently modified their holdings of the stock. Quarry LP bought a new position in Cellebrite DI in the 3rd quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares during the period. Advisors Asset Management Inc. boosted its stake in Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the period. Pathway Financial Advisers LLC grew its holdings in Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in Cellebrite DI during the 2nd quarter worth $71,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 1.1 %

Shares of CLBT stock opened at $21.81 on Tuesday. Cellebrite DI has a 12 month low of $7.91 and a 12 month high of $22.91. The company’s fifty day simple moving average is $20.46 and its 200-day simple moving average is $17.34. The firm has a market cap of $4.49 billion, a PE ratio of -14.07, a P/E/G ratio of 2.71 and a beta of 1.46.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 EPS. On average, equities analysts predict that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.